Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medihoney versus mupirocin strategy for prevention of peritoneal dialysis catheter infections
ACTRN12607000537459Phase 3Completed
- Sponsor
- Australasian Kidney Trials Network
- Start
- Sep 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of Medihoney Wound Gel and mupirocin in chronic kidney disease (CKD) and Peritoneal dialysis catheter infection, sponsored by Australasian Kidney Trials Network. Primary endpoint: Time to first catheter-associated infection. Started Sep 2008; status: completed.
02
Drugs
Medihoney Wound Gelmupirocin
03
Conditions
chronic kidney disease (CKD)Peritoneal dialysis catheter infection
Beyond the preview
Go deeper on ACTRN12607000537459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000537459.